npj Parkinsons Disease

Article	Citations
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions	301
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology	176
Subthalamic nucleus in patients with Parkinson’s disease encodes changes and magnitude of applied force	143
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances	129
Investigating the ageing-Parkinson’s disease nexus: standardisation of in vitro models and techniques by the PD-AGE network	128
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome	124
Biological aging predicts mortality in Parkinson’s patients: evidence from UK Biobank	118
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein	113
Longitudinal non-negative matrix factorization identifies the altered trajectory of motor symptoms in Parkinson’s disease	108
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI	107
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease	103
Physiotherapy interventions for balance impairments in Parkinson’s disease: evidence from a systematic review and dose-response meta-analysis	94
Machine learning integration of serial blood biomarkers enhances cognitive decline prediction in early Parkinson’s disease	94
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease	92
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders	86
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease	85
Differences in brain aging between sexes in Parkinson’s disease	84
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease	83
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective	83
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease	81
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease	80
Video-based machine learning models for predicting deep brain stimulation outcomes in Parkinson’s disease patients	79
Phase II pilot randomized trial of zonisamide for disease modification in prodromal Lewy body disease	78
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study	76
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease	72

Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population	71
Direct disassembly of α-syn preformed fibrils into α-syn monomers by an all-D-peptide	71
Position paper: leveraging non-human primate (NHP) specificities to accelerate Parkinson’s disease and ageing research	71
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies	70
The pattern of fMRI activation with STN DBS reveals symptom-specific networks	69
The IC-SNc neural circuit mediates prepulse inhibition deficits in MPTP-induced Parkinson’s disease male mice	65
The gut microbiome promotes mitochondrial respiration in the brain of a Parkinson’s disease mouse model	65
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings	63
Advanced brain aging in Parkinson’s disease with cognitive impairment	61
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease	60
The experience of Anxiety for people with Parkinson’s disease	60
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease	59
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD	59
Targeting the hypothalamic a11 nucleus to treat parkinsonian-like nociceptive impairments	58
Machine learning prediction of discharge destination in patients with Parkinson’s disease; a nationwide cohort study	58
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	57
Association of the number of minor hallucinations and well-structured visual hallucinations in Parkinson’s disease	55
Elevated levels of colonic interleukin-1beta and interleukin-8 in isolated REM sleep behavior disorder without associated changes in permeability	55
JNK3 quantification in plasma: a novel biomarker for neuronal damage in Parkinson’s disease	55
Single-cell analysis of the peripheral immune landscape in Parkinson’s disease: insights into dendritic cell and CD4+ T-cell transcriptomics	54
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?	54
Optimizing the MDS-UPDRS Part III for early-stage Parkinson’s: early supportive evidence for a limb-related bradykinesia/rigidity sub-score	54
In memorium, Michael Zigmond, PhD	54
Resting and action tremor in Parkinson’s disease: pathophysiological insights from long-term STN-DBS	53
Functional network differences between unilateral and bilateral deep brain stimulation of the subthalamic nucleus	51
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism	50
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis	50
Impaired migratory phenotype of CD4+ T cells in Parkinson’s disease	50
Inhibition of T cell infiltration and soluble TNF signaling is neuroprotective in the alpha-synuclein overexpressing mouse model of Parkinson’s disease	49
Butyrate improves abnormal sleep architecture in a Parkinson’s disease mouse model via BDNF/TrkB signaling	48
Park7 deletion leads to sex-specific transcriptome changes involving NRF2-CYP1B1 axis in mouse midbrain astrocytes	47
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway	46
Does Black vs. White race affect practitioners’ appraisal of Parkinson’s disease?	46
Cortical macro- and microstructural changes in isolated rapid eye movement sleep behavior disorder	45
Enrichment of gut-derived metabolites in a Parkinson’s disease subtype with REM sleep behavior disorder	45
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia	44
Lrrk2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis	44
Antiviral innate immunity induces alpha synuclein phosphorylation at serine129 in neurons independent of aggregation	44
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease	43
Synuclein phosphorylation: pathogenic or physiologic?	43
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease	42
Cryopreservable dopaminergic progenitors derived from human iPSCs with accelerated loss of pluripotency and early functional restoration in Parkinsonian rats	41
Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease	41
Immunological shifts during early-stage Parkinson’s disease identified with DNA methylation data on longitudinally collected blood samples	41
Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality	41
A systematic review and meta-analysis of the prevalence of Parkinson’s disease in lower to upper-middle-income countries	40
Mapping the developmental path for Parkinson’s disease therapeutics	39
A skin-specific α-Synuclein seeding amplification assay for diagnosing Parkinson’s disease	39
Diurnal modulation of subthalamic beta oscillatory power in Parkinson’s disease patients during deep brain stimulation	39
C/EBPβ/AEP is age-dependently activated in Parkinson’s disease and mediates α-synuclein in the gut and brain	38

Head-to-head comparison of four cerebrospinal fluid and three plasma neurofilament light chain assays in Parkinsonism	38
Tau seeding activity in skin biopsy differentiates tauopathies from synucleinopathies	37
Brain-region-specific lipid dysregulation in L-DOPA-induced dyskinesia in a primate model of Parkinson’s disease	37
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease	37
A 6-month longitudinal study on worsening of Parkinson’s disease during the COVID-19 pandemic	37
Increased frontal [123I]FP-CIT binding in Parkinson’s disease patients with self-reported REM sleep behavior disorder	37
Analysis of striatal connectivity corresponding to striosomes and matrix in de novo Parkinson’s disease and isolated REM behavior disorder	36
Oral health implications in Parkinson’s disease	36
Longitudinal multi-omics in alpha-synuclein Drosophila model discriminates disease- from age-associated pathologies in Parkinson’s disease	36
Testing an inverse link between limbic alpha-synucleinopathy and myelin markers in mice and humans	35
Modulatory effect of levodopa on the basal ganglia-cerebellum connectivity in Parkinson’s disease	35
Clinical symptoms and neuroanatomical substrates of daytime sleepiness in Parkinson’s disease	35
Prevalence of low muscle mass and its association with orthostatic hypotension and related symptoms in Parkinson’s disease	35
MAPKAPK2, a potential dynamic network biomarker of α-synuclein prior to its aggregation in PD patients	35
Construction of a mild cognitive impairment prediction model for Parkinson’s disease patients on the basis of multimodal data	35
Efficacy of deep brain stimulation of the subthalamic nucleus versus globus pallidus internus on sensory complaints	35
Personality profile and its association with conversion to neurodegenerative disorders in idiopathic REM sleep behavior disorder	34
Imaging and genome-supported association of glymphatic system function and multiregional brain characteristics with Parkinson’s disease	34
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases	34
Differentiating tremor-dominant parkinson’s disease from essential tremor using neuromelanin- sensitive imaging and T1w/T2w ratio	34
Hyposmia in Parkinson’s disease; exploring selective odour loss	33
TMEM175, SCARB2 and CTSB associations with Parkinson’s disease risk across populations	33
Neurophysiological gradient in the Parkinsonian subthalamic nucleus as a marker for motor symptoms and apathy	33
Plasma GFAP and NfL associate with cerebral glucose metabolism in putative brain-first and body-first Parkinson’s disease subtypes	33
Transcranial static magnetic field stimulation of the primary motor cortex in essential tremor: a randomized pilot study	32
Proceedings of the world summit on parkinson’s disease	32
A framework for translational therapy development in deep brain stimulation	32
Digital phenotyping of Parkinson’s disease via natural language processing	31
Candidate biomarkers of EV-microRNA in detecting REM sleep behavior disorder and Parkinson’s disease	31
Peripheral inflammation’s variable impact on cognitive and symptomatic outcomes in Parkinson’s disease: a longitudinal and cross-sectional analysis	31
Associations of digestive diseases exposure and lifestyle factors with Parkinson’s disease	31
Neuroprotection of low dose carbon monoxide in Parkinson’s disease models commensurate with the reduced risk of Parkinson’s among smokers	30
Matters arising: In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	30
DAT-SPECT-based subtype and stage inference in Parkinson’s disease	30
Impaired neuron differentiation in GBA-associated Parkinson’s disease is linked to cell cycle defects in organoids	30
STN-DBS does not increase the risk of sialorrhea in patients with advanced Parkinson’s disease	30
Predictors of stress resilience in Parkinson’s disease and associations with symptom progression	30
Using a smartwatch and smartphone to assess early Parkinson’s disease in the WATCH-PD study over 12 months	30
AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies	30
Exploring the genetic and genomic connection underlying neurodegeneration with brain iron accumulation and the risk for Parkinson’s disease	29
Brain age gap as predictor of disease progression in Parkinson’s disease	29
A novel peptide-based strategy to enhance GBA1 expression for treating Parkinson’s disease	29
Time to workforce exit after a Parkinson’s disease diagnosis	29
Lipid profiling of Parkinson’s disease brain highlights disruption in Lysophosphatidylcholines, and triacylglycerol metabolism	29
Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study	28
Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism	28
Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)	28
Towards scalable screening for the early detection of Parkinson’s disease: validation of an iPad-based eye movement assessment system against a clinical-grade eye tracker	28
PDCD4 triggers α-synuclein accumulation and motor deficits via co-suppressing TFE3 and TFEB translation in a model of Parkinson’s disease	28
Pathophysiological evaluation of the LRRK2 G2385R risk variant for Parkinson’s disease	28
Identifying maximal beta power from directional subthalamic local field potentials in Parkinson’s disease	27
Safety and efficacy of faecal microbiota transplantation in Parkinson’s disease	27
Exploring the link between essential tremor and Parkinson’s disease	27
Machine learning-based prediction of cognitive outcomes in de novo Parkinson’s disease	27
Possible role of lncRNAs in amelioration of Parkinson’s disease symptoms by transplantation of dopaminergic cells	27
Association of glymphatic system function with peripheral inflammation and motor symptoms in Parkinson’s disease	27
Cannabinoid regulation of angiotensin II-induced calcium signaling in striatal neurons	27
Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease	26
Development of a simplified smell test to identify Parkinson’s disease using multiple cohorts, machine learning and item response theory	26
To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson’s disease	26
Diagnostic utility of 7T neuromelanin imaging of the substantia nigra in Parkinson’s disease	26
Sleep disorders in Parkinson’s disease, an early and multiple problem	26
Mendelian randomization reveals association between retinal thickness and non-motor symptoms of Parkinson’s disease	26
Central biogenic amine deficiency with concomitant exploratory behavioral deficits in Dnajc12 knock-out mice	25
Data-driven subtyping of early Parkinson’s disease via mutual cross-attention fusion of EEG and dual-task gait features	25
Brain-clinical biotyping in patients with idiopathic REM sleep behavior disorder	25
Aerobic exercise-induced changes in fluid biomarkers in Parkinson’s disease	25
EEG alpha peak frequency: cognitive impairment severity marker in isolated REM sleep behavior disorder	25
Immune and metabolic signatures characterise constipation-driven endophenotypes in Parkinson’s disease	25
Video-based quantification of hand postural tremor without external references. Integrating postural tremor quantification into visionMD	25
Spatial single-cell multiomics reveals peripheral immune dysfunction in Parkinson’s and inflammatory bowel disease	25
Lack of full sequencing GBA1 studies for patients with Parkinson’s disease in Latin America	25
Association of wearable sensor-based gait analysis with phenoconversion trajectories in idiopathic REM sleep behavior disorder	24
Sentence completion in progressive supranuclear palsy following transcranial direct current stimulation	24
Modified version of unified multiple system atrophy rating scale for remote video-based assessments	24
A spatiotemporal hypergraph self-attention neural networks framework for the identification and pharmacological efficacy assessment of Parkinson’s disease motor symptoms	24
Self-perceived life course sleep duration trajectories and risk and age at onset of Parkinson’s disease	24
Inhibition of de novo ceramide synthesis mitigates alpha-synuclein pathology in a Parkinson’s disease mouse model	24
Genetically-informed prediction of short-term Parkinson’s disease progression	24
Genome-wide association study of copy number variations in Parkinson’s disease	24

α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies	23
Structural underpinnings and long-term effects of resilience in Parkinson’s disease	23
Glutamatergic synaptic resilience to overexpressed human alpha-synuclein	23
Misfolded protein deposits in Parkinson’s disease and Parkinson’s disease-related cognitive impairment, a [11C]PBB3 study	23
Spatial variations and precise location of substantia nigra hyperechogenicity in Parkinson’s disease using TCS-MR fusion imaging	23
Plasma biomarkers of neurodegeneration in patients and high risk subjects with Lewy body disease	23
Subthalamic nucleus input-output dynamics are correlated with Parkinson’s burden and treatment efficacy	23
Varying patterns of association between cortical large-scale networks and subthalamic nucleus activity in Parkinson’s disease	23
Clinical subtypes in patients with isolated REM sleep behaviour disorder	23
Synaptic vesicle characterization of iPSC-derived dopaminergic neurons provides insight into distinct secretory vesicle pools	23
Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson’s disease patients	23
The effect of pallidal stimulation on sleep outcomes and related brain connectometries in Parkinson’s disease	23
Author Correction: Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset	22
Prevalence of experienced changes in artistic and everyday creativity in people with Parkinson’s disease	22
Different effect of hypo- and hypermetabolism on cognition in dementia with Lewy bodies: are they coupled or independent?	22
A meta-analysis of the diagnostic utility of biomarkers in cerebrospinal fluid in Parkinson’s disease	22
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease	22
Prospective controlled study on the effects of deep brain stimulation on driving in Parkinson’s disease	22
Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies	22
A generalizable and open-source algorithm for real-life monitoring of tremor in Parkinson’s disease	22
In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease	22
Discovering genetic mechanisms underlying the co-occurrence of Parkinson’s disease and non-motor traits	22
Microstructural but not macrostructural cortical degeneration occurs in Parkinson’s disease with mild cognitive impairment	22
The biological clock in parkinson’s disease: mechanisms and chronotherapy	21
Advancements in invasive and non-invasive neuromodulation for Parkinson’s disease: current findings and future directions	21
Using former carers’ expertise in peer support for carers of people with Parkinson’s Disease	21
Novel co-culture model of T cells and midbrain organoids for investigating neurodegeneration in Parkinson’s disease	21
Influences of amyloid-β and tau on white matter neurite alterations in dementia with Lewy bodies	21
Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease	21
A systematic review of brain morphometry related to deep brain stimulation outcome in Parkinson’s disease	21
Subthalamic nucleus deep brain stimulation alleviates oxidative stress via mitophagy in Parkinson’s disease	21
Intracellular α-synuclein assemblies are sufficient to alter nanoscale diffusion in the striatal extracellular space	21
Evaluation of the PREDIGT score’s performance in identifying newly diagnosed Parkinson’s patients without motor examination	20
Lysosomal and synaptic dysfunction markers in longitudinal cerebrospinal fluid of de novo Parkinson’s disease	20
Transcranial direct current stimulation for Parkinson’s disease: systematic review and meta-analysis of motor and cognitive effects	20
Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei	20
Comprehensive real time remote monitoring for Parkinson’s disease using Quantitative DigitoGraphy	20
Pallidal beta power is associated with depression in Parkinson’s disease	20
Modulation of subthalamic beta oscillations by movement, dopamine, and deep brain stimulation in Parkinson’s disease	20
Population fraction of Parkinson’s disease attributable to preventable risk factors	20
Metagenomics indicates an interplay of the microbiome and functional pathways in Parkinson’s disease	20
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity	20
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease	20
Transcriptomic imputation of genetic risk variants uncovers novel whole-blood biomarkers of Parkinson’s disease	20
Direct and indirect regulation of β-glucocerebrosidase by the transcription factors USF2 and ONECUT2	20
rTMS improves dysphagia by inhibiting NLRP3 inflammasome activation and caspase-1 dependent pyroptosis in PD mice	19
Perivascular spread of CSF-derived α-synuclein oligomers drives region-specific Parkinson’s-like pathology	19
Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition	19
Different risks of early-onset and late-onset Parkinson disease in individuals with mental illness	19
Neurocognitive correlates of semantic memory navigation in Parkinson’s disease	19
Effects of deep brain stimulation frequency on eye movements and cognitive control	19
Unraveling the role of GBA1 genotype in axial signs response to subthalamic deep brain stimulation	19
Cerebral perfusion imaging predicts levodopa-induced dyskinesia in Parkinsonian rat model	19
Prominent role of PM10 in the link between air pollution and incident Parkinson’s Disease	19
Baseline cerebral structural morphology predict freezing of gait in early drug-naïve Parkinson’s disease	19
Towards a methodological uniformization of environmental risk studies in Parkinson’s disease	19
Atrophy of ventral diencephalon is associated with freezing of gait in Parkinson’s disease: analysis of two cohorts	18
Independent serum metabolomics approaches identify disrupted glutamic acid and serine metabolism in Parkinson’s disease patients	18
Altered wakeful theta activity characterizes levodopa-induced dyskinesia in Parkinson’s disease	18
High-resolution mapping of substantia nigra in Parkinson’s disease using 7 tesla magnetic resonance imaging	18
Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson’s disease: A systematic review	18
MRI subtypes in Parkinson’s disease across diverse populations and clustering approaches	18
StimVision: smartphone video kinematics to optimize DBS programming in Parkinson’s disease	18
Multi-omic insight into the molecular mechanism of cuproptosis-related genes in the pathogenesis of Parkinson’s disease	18
Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson’s disease	18
Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson’s Disease	18
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease	18
AccessPD as a next generation registry to accelerate Parkinson’s disease research	18
The barriers to receiving health care for people with Parkinson’s from predominantly Asian backgrounds in the UK	18
Social isolation and the risk of Parkinson disease in the UK biobank study	18
Exploring glymphatic system alterations in iRBD and Parkinson’s disease using automated DTI-ALPS analysis	18
Driving motor cortex oscillations restores plasticity and improves bradykinesia features in Parkinson’s disease	18
Lysosomal genes contribute to Parkinson’s disease near agriculture with high intensity pesticide use	17
MRI data-driven clustering reveals different subtypes of Dementia with Lewy bodies	17
Author Correction: The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data	17
Inherent variability limits clinical utility of reproducible Parkinson’s transcriptomics signatures	17
Genetic analyses identify circulating genes related to brain structures associated with Parkinson’s disease	17
Long-term oral glucocerebrosidase activator reduces soluble α-synuclein oligomer accumulation in Parkinsonian LRRK2 mutant mouse brain	17
A single centre prospective study of three device-assisted therapies for Parkinson’s disease	17
Optimizing Parkinson’s disease progression scales using computational methods	17
Advancing age and the rs6265 BDNF SNP are permissive to graft-induced dyskinesias in parkinsonian rats	17
Regional-specific structural and functional changes of posterior cerebellar vermis across different stages of Parkinson’s disease with gait dysfunction	17
L-Dopa-modified microtubules lead to synapse instability in cultured neurons: possible implications in Parkinson’s disease therapy	17
Systematic evaluation of mitochondrial morphology regulators for amelioration of neuronal α-synucleinopathy	17
Synthetic MRI study of brain volume and subcortical myelin in various Parkinson’s disease motor subtypes	17
Accelerating Parkinson’s Disease drug development with federated learning approaches	16
Inflammatory CSF profiles and longitudinal development of cognitive decline in sporadic and GBA-associated PD	16
SNCA triplication disrupts proteostasis and extracellular architecture prior to neurodegeneration in human midbrain organoids	16
Circulating blood circular RNA in Parkinson’s Disease; from involvement in pathology to diagnostic tools in at-risk individuals	16
Association of fecal short-chain fatty acids with clinical severity and gut microbiota in essential tremor and its difference from Parkinson’s disease	16
Disruption of axonal transport in Parkinson’s disease: the role of pathological α-Syn and AMPK/p38 MAPK signaling	16
Clinico-imaging features of subjects at risk of Lewy body disease in NaT-PROBE baseline analysis	16
Wearable-sensor based walking and non-walking measures as progression markers in early to mid-stage Parkinson’s disease	16
Simulating the progression of brain structural alterations in Parkinson’s disease	16
Perspective on the current state of the LRRK2 field	16